Generic drug

regulatory bodies (WTO,2012). On the other hand, some of the pharmaceutical companies continuously tweaking the drug slightly to extend the life of the patent. Besides that, during the period patent protection, developing countries are prevented from importing or producing cheaper medicines, it

aggressive growth strategy, made possible by the demand for generic pharmaceuticals. Having established itself in South Africa, thanks to the local demand for generic antiretrovirals (ARVs) and tuberculosis (TB) treatments, the group has been able to expand through a focus on emerging markets, where demand for more affordable medicines is most prevalent. “Aspen identified the opportunity within the local market as it moved towards higher generic penetration,” says Investec Asset Management’s Neil Stuart-Findlay

Ranbaxy Laboratories Ltd. (RLL) is the largest pharmaceutical company incorporated in India. It is also amongst the top league globally and is ranked 9th largest generic company worldwide. Ranbaxy is also credited with the tag of true Indian multinational. The company traces its roots to a chemist shop in Delhi. It is one of the first Indian pharmaceutical company to start a joint venture abroad. Rapid growth of Ranbaxy is attributed mainly to its focused research and joint ventures in India and

Merck’s sales worldwide reached $48 billion in 2011, which was a 4% increase from 2010. With two drugs under review with the FDA, the company has 19 other drugs in the Phase III of development. b. Pfizer Inc.: History And Background Information Found by Charles Pfizer and Charles Erhart in 1849 Pfizer, Inc. is the largest pharmaceutical company in the world. Their main goal was to discover new drugs that would help improve the healthcare around the world. Both Pfizer and Erhart were born and

prescription drugs than any other industrialized country. In 2013, the United States spent $858 per capita compared to the average of $400 for 19 industrialized countries (Kesselheim, Avorn, & Sarpatwari, 2016). Prescription drug costs have significantly increased in recent years: from 2013 to 2015, prescription drug net spending increased to about 20%, which surpassed a forecast of an 11% increase (Kesselheim et al., 2016). Prescription drugs amount to 17% of total health care costs; prescription drug coverage

which provides competitive advantage to these firms, to continue to thrive in the market and grow. CRM is essential for Pharmaceutical and life sciences companies- with products ranging from Low involvement products to critical, high involvement products, the type of relationships between the companies, their channels, doctors and end customers are quite unique. It is a relationship built on trust and delivery. EFFECTS OF PHARMACEUTICAL CRM ON THE PRESCRIPTION GENERATION FROM DOCTORS Foundation

The Pharmaceutical Industry and the AIDS Crisis in Developing Countries · Describe the nature of supplying drugs to emerging markets at an affordable price without undermining their profits · Research and analyse in depth the effectiveness of one proposed policy response to this issue. Introduction 1 2001 saw a flurry of events, as highlighted in the excepts of the case study, which caused an awareness by the international community of the inequality between rich and poor nations in the care

pharmaceutical firm in India to consider building a joint venture together. Ranbaxy Laboratories began as a family business in the 1960’s, but with strong entrepreneurial skills the company grew to become one of the largest manufacturers for bulk drugs and generic drugs. The two companies considered pursuing a joint venture that would support on another’s products by supplying one other with ingredients to complete company products without having to trade with other companies internationally. The JV would

Chadron State College Executive Summary Dendreon Corporation faces tremendous potential with expansion into the Chinese market. The company is positioned for great expansion, just having received it Food and Drug Administration approval for its first drug, Provenge. The drug has wide-spread potential in the Chinese market that promises increasing life expectancy, rapidly growing disposable incomes, improving healthcare infrastructure, and evolving patent protection. When the possibility

behind the Transaction. The Transaction promises to bring some cheer to the Indian pharmaceutical industry. However, post the consummation of the Transaction, Sun Pharma has plans to gradually phase out the fifty-year old Ranbaxy brand, with Ranbaxy drugs sold in the United States being gradually rebranded